Article
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex
8 Dec 2014
Abstract excerpt
The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligand-independent mechanisms (including constitutively active AR splice variants) highlights the unmet need for alternative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
